Thermo Fisher Scientific (TMO) Liabilities and Shareholders Equity (2009 - 2026)

Thermo Fisher Scientific has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $113.3 billion for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 14.38% year-over-year to $113.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $427.9 billion (up 8.26% YoY) and the FY2025 annual result came in at $110.3 billion, up 13.38% from the prior year.
• Liabilities and Shareholders Equity improved to $113.3 billion in Q1 2026, from $110.3 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $113.3 billion in Q1 2026 and troughed at $90.5 billion in Q4 2022.
• A 5-year average of $98.6 billion and a median of $97.3 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 40.67% — and 2024, when it slipped 1.42%.
• Tracing TMO's Liabilities and Shareholders Equity over 5 years: stood at $97.2 billion in 2022, then grew by 1.62% to $98.7 billion in 2023, then dropped by 1.42% to $97.3 billion in 2024, then increased by 13.38% to $110.3 billion in 2025, then increased by 2.66% to $113.3 billion in 2026.
• Business Quant data shows TMO's Liabilities and Shareholders Equity at $113.3 billion in Q1 2026, $110.3 billion in Q4 2025, and $103.0 billion in Q3 2025.